Taken together with our findings, these observations suggest that type I IFN blockade may play an important role in SLE management through prevention/attenuation of subsequent flares of disease and through promotion of a low disease activity state, particularly in difficult-to-treat patients with high baseline IFN-induced gene expression. This evidence concerns the gene IFNA1 and systemic lupus erythematosus.